ESMO Congress 2023

The European Society for Medical Oncology (ESMO) Congress brings together oncologists from around the world to learn about the latest data and clinical updates in oncology. ESMO 2023 takes place October 20 - 24 in Madrid, Spain, with a virtual attendance option. Participants have the opportunity to interact with key opinion leaders, network with colleagues, and ask questions and debate on key topics in the field of medical oncology.

Faculty from the Mass General Cancer Center will present at ESMO 2023, sharing their latest work via oral and paper sessions and leading panel discussions.

Aditya Bardia, MD

Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With Solid Tumors Harboring Specific HER2-activating Mutations (HER2m): Primary Results From the International Phase 2 DESTINY-PanTumor01 (DPT-01) Study
October 22 at 9:20 a.m. - 9:30 a.m.
Málaga Auditorium - Hall 10

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Previously Treated Inoperable or Metastatic Hormone Receptor-positive, HER2-negative (HR+/HER2–) Breast Cancer (BC): Primary Results From the Randomised Phase 3 TROPION-Breast01 Trial
October 23 at 4:30 p.m. - 4:42 p.m.
Madrid Auditorium - Hall 6

Invasive Disease–free Survival (iDFS) Across Key Subgroups From the Phase III NATALEE Study of Ribociclib (RIB) + a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (pts) With HR+/HER2− Early Breast Cancer (EBC)
October 23 at 5:05 p.m. - 5:10 p.m.
Bilbao Auditorium - NCC

Xin Gao, MD

The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan (SG) Plus Enfortumab Vedotin (EV) as ≥ Second Line Therapy for Metastatic Urothelial Carcinoma (mUC)
October 21 at 9:10 a.m. - 9:20 a.m.
Barcelona Auditorium - Hall 9

Aaron Hata, MD, PhD

Clinical Subtyping of Cancer From Blood Based on Comprehensive Epigenomic Profiling
October 21 at 10:25 a.m. - 10:35 a.m.
Salamanca Auditorium - Hall 3

Rebecca Heist, MD, MPH

TROPION-Lung05: Datopotamab Deruxtecan (Dato-DXd) in Previously Treated Non-small Cell Lung Cancer (NSCLC) With Actionable Genomic Alterations (AGAs)
October 21 at 9:30 a.m. - 9:35 a.m.
Granada Auditorium - Hall 3

Sam Klempner, MD

Heterogeneity, Evolution, and Outcomes in Gastroesophageal Cancer
October 21 at 10:20 a.m. - 10:35 a.m.
Granada Auditorium - Hall 3

Jessica Lin, MD

Managing Progression After TKIs in Oncogenic Fusion-driven Lung Cancer
October 21 at 3:35 p.m. - 4:15 p.m.
Granada Auditorium - Hall 3

Invited Discussant 1319MO, 1321MO and 1324MO in Mini Oral Session 2 - NSCLC, Metastatic
October 22 at 9:15 a.m. - 9:30 a.m.
Sevilla Auditorium - Hall 9

M. Dror Michaelson, MD, PhD

The Double Antibody Drug Conjugate (DAD) Phase I trial: Sacituzumab Govitecan (SG) Plus Enfortumab Vedotin (EV) as ≥ Second Line Therapy for Metastatic Urothelial Carcinoma (mUC)
October 21 at 9:10 a.m. - 9:20 a.m.
Barcelona Auditorium - Hall 9

Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
October 21 at 2:45 p.m. - 2:55 p.m.
Barcelona Auditorium - Hall 9

Aparna Parikh, MD

Targeting KRAS in GI Cancers: Where Are We Now?
October 23 at 1:30 p.m. - 1:55 p.m.
Valencia Auditorium - Hall 10

Locally Advanced dMMR/MSI-H Rectal Cancer: New Approaches Under Investigation
October 23 at 6:45 p.m. - 7:05 p.m.
Burgos Auditorium - Hall 3

Jeffrey Peppercorn, MD, MPH

The Impact of Proton Pump Inhibitor (PPI) Exposure Before Immune Checkpoint Inhibitor (ICI) Therapy on Overall Survival (OS): A Population-based Study
October 21 at 2:55 p.m. - 3:00 p.m.
Toledo Auditorium - Hall 3

Zosia Piotrowska, MD, MHS

Presentation by Expert EGFR - First-line Treatment of EGFR Mutated NSCLC: Choosing Between Many Options
October 20 at 2:15 p.m. - 3:00 p.m.
Valencia Auditorium - Hall 10

Improving HER2 Targeting in NSCLC With Selective TKI
October 20 at 6:25 p.m. - 6:50 p.m.
Oviedo Auditorium - Hall 7

Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer
October 20 at 7:25 p.m. - 7:30 p.m.
Oviedo Auditorium - Hall 7

Invited Discussant LBA14 and LBA15 in Proffered Paper Session - Presidential 3
October 23 at 5:59 p.m. - 6:09 p.m.
Madrid Auditorium - Hall 6

Helen Shih, MD

Radiotherapy for Low Grade Gliomas With and Without Mutations: Wait or Treat?
October 23 at 3:30 p.m. - 3:45 p.m.
León Auditorium - Hall 7

Ryan Sullivan, MD

Chair: When Does Targeted Therapy Outperform Immunotherapy in Patients With Advanced Melanoma?
October 20 at 4:35 p.m. - 5:00 p.m.
Salamanca Auditorium - Hall 3

Revisiting Old Friends: New Clinical Developments of MEKi/BRAFi/NRASi Combinations
October 21 at 10:20 a.m. - 10:40 a.m.
Burgos Auditorium - Hall 3

Three-year Survival With Tebentafusp in Previously Untreated Metastatic Uveal Melanoma in a Phase 3 Trial
October 21 at 3:10 p.m. - 3:15 p.m.
León Auditorium - Hall 7

mRNA-4157 (V940) Individualized Neoantigen Therapy + Pembrolizumab vs Pembrolizumab in High-risk Resected Melanoma: Clinical Efficacy and Correlates of Response
October 23 at 8:40 a.m. - 8:50 a.m.
Valencia Auditorium - Hall 10

Lori Wirth, MD

Randomized Phase 3 Study of Selpercatinib versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer
October 21 at 5:10 p.m. - 5:22 p.m.
Madrid Auditorium - Hall 6